Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply

Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ide...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2024-08, Vol.404 (10451), p.434-434
Main Authors: Al-Samkari, Hanny, B Bussel, James, Miyakawa, Yoshi, Broome, Catherine M
Format: Article
Language:English
Subjects:
Blood
Blood platelets
Children
Clinical trials
Fc receptors
Fetuses
Humans
Idiopathic thrombocytopenic purpura
Incompatibility
Laboratories
Neonates
Platelets
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Quality of life
Randomized Controlled Trials as Topic
Research funding
Thrombocytopenia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c1864-38027d1035b99ee9f6252e6b6ba24a3c2edea96f797053d807eadc69af3d627a3
container_end_page 434
container_issue 10451
container_start_page 434
container_title The Lancet (British edition)
container_volume 404
creator Al-Samkari, Hanny
B Bussel, James
Miyakawa, Yoshi
Broome, Catherine M
description Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ideally, advances in testing will reliably allow additional such evaluations in the future to better evaluate the mechanism of treatment effect and potentially allow for the establishment of laboratory profiles that predict response. JBB reports honoraria from Novartis, Sobi, Alpine, UCB, argenx, Janssen, and RallyBio; and unpaid leadership roles in a board, society, or advocacy group with Platelet Disorder Society of America, Children's Cancer and Blood Foundation, and Foundation for Women and Girls with Blood Disorders.
doi_str_mv 10.1016/S0140-6736(24)01263-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3087699263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673624012637</els_id><sourcerecordid>3087699263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1864-38027d1035b99ee9f6252e6b6ba24a3c2edea96f797053d807eadc69af3d627a3</originalsourceid><addsrcrecordid>eNqFkMtu1DAUhi1ERYfCI4AssaBdBHyLHbNBo-lAK1V00YtgZTn2SesqiQc7QZpd36FvyJOQzgxdsGF1pKPv_8_Rh9AbSj5QQuXHC0IFKaTi8pCJI0KZ5IV6hmZUKFGUQn1_jmZPyD56mfMdIURIUr5A-1wTrbgWM_Rj2dzYNISb0EWPm5jwKoXOpjUOXTf2gIfbFLs6uvUQV9AH-2naAJ4fX8-_LZb49BoPKdgW_75_wPNxuI0pv8cJVu36FdprbJvh9W4eoKsvy8vFSXF2_vV0MT8rHK2kKHhFmPKU8LLWGkA3kpUMZC1ry4TljoEHq2WjtCIl9xVRYL2T2jbcS6YsP0CH295Vij9HyIPpQnbQtraHOGbDSaWk1pOfCX33D3oXx9RP320oWglKqokqt5RLMecEjdkpMZSYR_dm4948ijVMmI17o6bc2137WHfgn1J_ZU_A5y0Ak45fAZLJLkDvwIcEbjA-hv-c-ANPI5La</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3087184108</pqid></control><display><type>article</type><title>Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply</title><source>ScienceDirect Freedom Collection</source><creator>Al-Samkari, Hanny ; B Bussel, James ; Miyakawa, Yoshi ; Broome, Catherine M</creator><creatorcontrib>Al-Samkari, Hanny ; B Bussel, James ; Miyakawa, Yoshi ; Broome, Catherine M</creatorcontrib><description>Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ideally, advances in testing will reliably allow additional such evaluations in the future to better evaluate the mechanism of treatment effect and potentially allow for the establishment of laboratory profiles that predict response. JBB reports honoraria from Novartis, Sobi, Alpine, UCB, argenx, Janssen, and RallyBio; and unpaid leadership roles in a board, society, or advocacy group with Platelet Disorder Society of America, Children's Cancer and Blood Foundation, and Foundation for Women and Girls with Blood Disorders.</description><identifier>ISSN: 0140-6736</identifier><identifier>ISSN: 1474-547X</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(24)01263-7</identifier><identifier>PMID: 39097394</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Blood ; Blood platelets ; Children ; Clinical trials ; Fc receptors ; Fetuses ; Humans ; Idiopathic thrombocytopenic purpura ; Incompatibility ; Laboratories ; Neonates ; Platelets ; Purpura, Thrombocytopenic, Idiopathic - drug therapy ; Quality of life ; Randomized Controlled Trials as Topic ; Research funding ; Thrombocytopenia</subject><ispartof>The Lancet (British edition), 2024-08, Vol.404 (10451), p.434-434</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1864-38027d1035b99ee9f6252e6b6ba24a3c2edea96f797053d807eadc69af3d627a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39097394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Samkari, Hanny</creatorcontrib><creatorcontrib>B Bussel, James</creatorcontrib><creatorcontrib>Miyakawa, Yoshi</creatorcontrib><creatorcontrib>Broome, Catherine M</creatorcontrib><title>Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ideally, advances in testing will reliably allow additional such evaluations in the future to better evaluate the mechanism of treatment effect and potentially allow for the establishment of laboratory profiles that predict response. JBB reports honoraria from Novartis, Sobi, Alpine, UCB, argenx, Janssen, and RallyBio; and unpaid leadership roles in a board, society, or advocacy group with Platelet Disorder Society of America, Children's Cancer and Blood Foundation, and Foundation for Women and Girls with Blood Disorders.</description><subject>Blood</subject><subject>Blood platelets</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Fc receptors</subject><subject>Fetuses</subject><subject>Humans</subject><subject>Idiopathic thrombocytopenic purpura</subject><subject>Incompatibility</subject><subject>Laboratories</subject><subject>Neonates</subject><subject>Platelets</subject><subject>Purpura, Thrombocytopenic, Idiopathic - drug therapy</subject><subject>Quality of life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Research funding</subject><subject>Thrombocytopenia</subject><issn>0140-6736</issn><issn>1474-547X</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkMtu1DAUhi1ERYfCI4AssaBdBHyLHbNBo-lAK1V00YtgZTn2SesqiQc7QZpd36FvyJOQzgxdsGF1pKPv_8_Rh9AbSj5QQuXHC0IFKaTi8pCJI0KZ5IV6hmZUKFGUQn1_jmZPyD56mfMdIURIUr5A-1wTrbgWM_Rj2dzYNISb0EWPm5jwKoXOpjUOXTf2gIfbFLs6uvUQV9AH-2naAJ4fX8-_LZb49BoPKdgW_75_wPNxuI0pv8cJVu36FdprbJvh9W4eoKsvy8vFSXF2_vV0MT8rHK2kKHhFmPKU8LLWGkA3kpUMZC1ry4TljoEHq2WjtCIl9xVRYL2T2jbcS6YsP0CH295Vij9HyIPpQnbQtraHOGbDSaWk1pOfCX33D3oXx9RP320oWglKqokqt5RLMecEjdkpMZSYR_dm4948ijVMmI17o6bc2137WHfgn1J_ZU_A5y0Ak45fAZLJLkDvwIcEbjA-hv-c-ANPI5La</recordid><startdate>20240803</startdate><enddate>20240803</enddate><creator>Al-Samkari, Hanny</creator><creator>B Bussel, James</creator><creator>Miyakawa, Yoshi</creator><creator>Broome, Catherine M</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20240803</creationdate><title>Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply</title><author>Al-Samkari, Hanny ; B Bussel, James ; Miyakawa, Yoshi ; Broome, Catherine M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1864-38027d1035b99ee9f6252e6b6ba24a3c2edea96f797053d807eadc69af3d627a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Blood</topic><topic>Blood platelets</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Fc receptors</topic><topic>Fetuses</topic><topic>Humans</topic><topic>Idiopathic thrombocytopenic purpura</topic><topic>Incompatibility</topic><topic>Laboratories</topic><topic>Neonates</topic><topic>Platelets</topic><topic>Purpura, Thrombocytopenic, Idiopathic - drug therapy</topic><topic>Quality of life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Research funding</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Samkari, Hanny</creatorcontrib><creatorcontrib>B Bussel, James</creatorcontrib><creatorcontrib>Miyakawa, Yoshi</creatorcontrib><creatorcontrib>Broome, Catherine M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Samkari, Hanny</au><au>B Bussel, James</au><au>Miyakawa, Yoshi</au><au>Broome, Catherine M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2024-08-03</date><risdate>2024</risdate><volume>404</volume><issue>10451</issue><spage>434</spage><epage>434</epage><pages>434-434</pages><issn>0140-6736</issn><issn>1474-547X</issn><eissn>1474-547X</eissn><abstract>Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ideally, advances in testing will reliably allow additional such evaluations in the future to better evaluate the mechanism of treatment effect and potentially allow for the establishment of laboratory profiles that predict response. JBB reports honoraria from Novartis, Sobi, Alpine, UCB, argenx, Janssen, and RallyBio; and unpaid leadership roles in a board, society, or advocacy group with Platelet Disorder Society of America, Children's Cancer and Blood Foundation, and Foundation for Women and Girls with Blood Disorders.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39097394</pmid><doi>10.1016/S0140-6736(24)01263-7</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2024-08, Vol.404 (10451), p.434-434
issn 0140-6736
1474-547X
1474-547X
language eng
recordid cdi_proquest_miscellaneous_3087699263
source ScienceDirect Freedom Collection
subjects Blood
Blood platelets
Children
Clinical trials
Fc receptors
Fetuses
Humans
Idiopathic thrombocytopenic purpura
Incompatibility
Laboratories
Neonates
Platelets
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Quality of life
Randomized Controlled Trials as Topic
Research funding
Thrombocytopenia
title Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A04%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efgartigimod%20for%20primary%20immune%20thrombocytopenia:%20the%20ADVANCE%20IV%20trial%20%E2%80%93%20Authors'%20reply&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Al-Samkari,%20Hanny&rft.date=2024-08-03&rft.volume=404&rft.issue=10451&rft.spage=434&rft.epage=434&rft.pages=434-434&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(24)01263-7&rft_dat=%3Cproquest_cross%3E3087699263%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1864-38027d1035b99ee9f6252e6b6ba24a3c2edea96f797053d807eadc69af3d627a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3087184108&rft_id=info:pmid/39097394&rfr_iscdi=true